Pharmadule
Morimatsu has successfully completed the first SARS CoV-2
mRNA vaccine production plant to Chinese vaccine manufacturer
WALVAX.
The 5-story, 6 000 m2
facility was designed and fabricated according to WHO regulations.
Pharmadule Morimatsu provided a "one-stop" solution from basic
design, detail design, equipment fabrication, modular construction
to transportation, on-site installation and commissioning.
The modular factory and
process systems were fabricated and commissioned simultaneously
with the on-site civil construction works. The modular fabrication
in Pharmadule Morimatsu´s well-equipped factory in Shanghai,
enabled more than 80% of the work to be completed before shipping.
The overall delivery time of 7,5 months was more than half compared
with traditional projects. This effectively accelerated the
production of the mRNA coronavirus vaccine in China.
